Nanoparticles formulation

Stevens PJ, Sekido M, Lee RJ. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm Res 2004 21 2153. 

Nanoparticles formulated with PLGA have been shown to be rapidly uptaken by the endothelial cells, the uptake was shown to depend on the nanoparticle concentration and the particles where mainly shown to localize in the cytoplasm (207). These nanoparticles were also shown to be biocompatible with the cells with no effect on cell viability (207). This is important due to the fact that endothelium is an important target for gene therapy in a number of disorders including angiogenesis, atherosclerosis, tumor growth, myocardial infarction, limb and cardiac ischemia, restenosis (207). 

S. Shelukar, G Kwei, and D. Storey (2004). The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869 a beagle dog model predicts improved bioavailability and diminished food effect on absorption in humlait). J. Pharm, 285 135-146. 

K. Kataoka, andT. Kakizoe. 2005. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extendh vivo antitumour activity and reduce the neurotoxicity of paclitafel.J. Cancer 92 1240-1246. 

Liu X, Howard KA, Dong M et al (2007) The influence of polymeric properties on chitosan/ siRNA nanoparticle formulation and gene silencing. Biomaterials 28(6) 1280—1288... 

C. Racles, T. Hamaide, A. loanid, Appl. Organometal. Chem. 2006,20(4), 235-245. Siloxane surfactants in polymer nanoparticles formulation. ... 

Ibrahim, N.K. Desai, N. Legha, S. Soon-Shiong, P. Theriault, R.L. Rivera, E. Esmaeli, B. Ring, S.E. Bedikian, A. Hortobagyi, G.N. Ellerhorst, J.A. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 2002, 8 (5), 1038-1044. 

Mykhaylyk O, Vlaskou D, Tresilwised N, Pithayanukul P, MoUer W, Plank C (2007) Magnetic nanoparticle formulations for DNA and siRNA delivery. J Magn Magn Mater 311 275-281... 

Development of novel nanoparticle formulations with improved stabilities and shelf-lives. 

Development of nanoparticle formulations for improved absorption of insoluble compounds and macromolecules enables improved bioavailability and release rates, potentially reducing the amount of dose required and increasing safety through reduced side effects. 

Manufacture of nanoparticle formulations with controlled particle sizes, morphology, and surface properties would be more effective and less expensive than other technologies. 

Nanoparticle formulations that can provide sustained-release profiles up to 24 h can improve patient compliance with drug regimens. 

Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H, Muro K, Yamada Y, Okusaka T, Shirao K, Shimada Y, Nakahama H, Matsumura Y. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer 2007 97 170-176. 

Shuhendler AJ, Chung R, Manias J, Connor A, Rauth AM, Wu XY. A novel doxombidn-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treatment, submitted in 2008. Dass CR, Choong PFM. Selective gene delivery for cancer therapy using cationic liposomes In vivo proof of applicability. J Control Release 2006 113 155-163. 

Ray B, Bisht S, Maitra A, Maitra A, Lahiri DK. Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurcT ) in the neuronal cell culture and animal model Implications for Alzheimer s disease. J Alzheimers Dis. 2011 23(l) 61-77. 

---